Monsanto Seeks $100 Million in Damages from Novartis

Monsanto says it has filed an arbitration claim against Novartis subsidiary Sandoz (Vienna) with the International Chamber of Commerce (Paris) over “quality assurance failures” at Sandoz’s Kundl, Austria pharmaceutical facility. Monsanto sources Posilac, an animal pharmaceutical supplement, from this facility. Monsanto says it is seeking $100 million in damages to compensate for “significant financial injury” resulting from supply disruptions to Monsanto customers that occurred while Sandoz was bringing its plant up to U.S. FDA...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers